

**IN THE CLAIMS**

1. (currently amended) A combination useful for simultaneous, sequential or separate administration in anticancer or antiviral therapy, product comprising calcium, injectable magnesium and an active ingredient which releases oxalate during its metabolism, ~~as a combination useful for simultaneous, sequential or separate administration in anticancer or antiviral therapy.~~

2. (currently amended) The combination of product ~~as claimed in claim 1, wherein characterized in that~~ part of the calcium is in injectable form and the other part is in oral form.

3. (currently amended) The combination product ~~as claimed in either of claims 1 and 2, wherein said active ingredient characterized in that the product which releases oxalate during its metabolism is~~ oxaliplatin.

4. (currently amended) The combination product ~~as claimed in any one of claims 1 to 3, wherein characterized in that~~ the calcium is in gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate form, and the magnesium is in sulfate or pidolate form.

5. (currently amended) The combination of product ~~as claimed in claim 4, characterized in that wherein~~ part of the calcium is in injectable form and the other part is in oral form, and wherein said ~~the concentrations of injectable calcium is present in a concentration are between 8 and 20 mg/ml, and wherein said and the concentrations of injectable magnesium is present in a concentration are between 10 and 20 mg/ml, preferably 15 mg/ml, (these concentrations being are expressed as calcium ions).~~

6. (currently amended) A method of preventing or treating neurotoxicity caused by the administration of a product that releases oxalate during its metabolism, comprising

administering to a patient~~The use of a combination of calcium and magnesium effective to prevent or treat the neurotoxicity for the preparation of a combination product intended to prevent or treat the neurotoxicity caused by the administration of a product which releases oxalate during its metabolism.~~

7. (currently amended) The method of use~~as claimed in claim 6, wherein characterized in that~~ part of the calcium is administered to the patient in injectable form and the other part is administered in oral form.

8. (currently amended) The method of use~~as claimed in claim 6, wherein characterized in that~~ the product which releases oxalate is oxaliplatin.

9. (new) The method of claim 7, wherein the calcium and magnesium are administered to the patient prior to, after, or both prior to and after administration of the product that releases oxalate during its metabolism.

10. (new) The method of claim 7, wherein the calcium and magnesium are administered to the patient simultaneously with administration of the product that releases oxalate during its metabolism.

11. (new) The method of claim 7, wherein said calcium and magnesium are administered separately.

12. (new) The combination of claim 5, wherein the concentration of said injectable magnesium is 15 mg/ml.